Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women
Phase 3
Completed
- Conditions
- Nausea and Vomiting, Postoperative
- Interventions
- Drug: GW679769 (casopitant)
- Registration Number
- NCT00326248
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 482
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm 1 GW679769 (casopitant) -
- Primary Outcome Measures
Name Time Method Rates of vomiting and retching after surgery
- Secondary Outcome Measures
Name Time Method Rates of nausea. Blood test results. after surgery
Trial Locations
- Locations (1)
GSK Investigational Site
🇬🇧Liverpool, United Kingdom